Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
|Articles|April 20, 2018
Novel Oral Anticoagulant Reversal Agent Tops AJPB Week in Review
Author(s)AJPB staff
Top news of the week from The American Journal of Pharmacy Benefits.
Advertisement
5. FDA OKs Treatment Combo for Advanced Renal Cell Carcinoma
Nivolumab plus low-dose ipilimumab combination is the first and only treatment to show significantly superior survival compared with sunitinib in intermediate- and poor-risk advanced renal cell carcinoma. Read more.
4. Congress, Medical Societies Address Approaches to Combat Opioid Crisis
Two different approaches to attack the opioid-fueled substance use disorder (SUD) crisis are on display this week. Read more.
3. Artificial Pancreas Improves Blood Sugar Control in Type 1 Diabetes
An artificial pancreas can improve blood sugar control for people with type 1 diabetes (T1D), according to a new study. Read more.
2. Childhood Factors May Contribute to COPD Risk
Childhood factors predisposed children to lung function decline and chronic obstructive pulmonary disease (COPD) as adults, according to 2 recent studies. Read more.
1. FDA Approves First Novel Oral Anticoagulant Reversal Agent
The approval is the first of its kind for a reversal agent of a novel oral anticoagulant (NOAC). Read more.
Advertisement
Related to this article
Increasingly, pharmacists are leading the obesity management team.
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
EMBER-3 data show switching to the combination at progression nearly doubled PFS versus imlunestrant alone in ESR1-mutated advanced breast cancer.
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
2
New Data Reshapes Nonstatin Lipid Therapy Choices
3
Etentamig Reduces Risk of Progression or Death by 60% in Relapsed/Refractory Multiple Myeloma
4
Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses
5